On the other hand, in aggressive and metastatic tumors, a combination of intercalating agents targeting cellular division with ADRB-2 blockers might reduce metastatic dissemination, as has been recently shown in metastatic paraganglioma [60,64]. This evidence concerns the gene ADRB2 and metastatic neoplasm.